Cargando…

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis

IFN-γ and IL-22 are deeply involved in the pathogenesis of psoriasis, as they boost the expression of inflammatory genes and alter proliferative and differentiative programs in keratinocytes. The JAK1/JAK2/STAT1 and JAK1/TYK2/STAT3 pathways triggered by IFN-γ and IL-22, respectively, are aberrantly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morelli, Martina, Scarponi, Claudia, Mercurio, Laura, Facchiano, Francesco, Pallotta, Sabatino, Madonna, Stefania, Girolomoni, Giampiero, Albanesi, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276416/ https://www.ncbi.nlm.nih.gov/pubmed/30581877 http://dx.doi.org/10.1155/2018/7897263

Ejemplares similares

PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial Inflammation: Implications for a Topically Druggable Target in Psoriasis
por: Mercurio, Laura, et al.
Publicado: (2021)

Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21
por: Mercurio, Laura, et al.
Publicado: (2020)

The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis
por: Albanesi, Cristina, et al.
Publicado: (2018)

Enhanced NAMPT-Mediated NAD Salvage Pathway Contributes to Psoriasis Pathogenesis by Amplifying Epithelial Auto-Inflammatory Circuits
por: Mercurio, Laura, et al.
Publicado: (2021)

Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis
por: Madonna, S, et al.
Publicado: (2012)

Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses
por: Mercurio, Laura, et al.
Publicado: (2020)

Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis
por: Morelli, Martina, et al.
Publicado: (2022)

Paradoxical psoriasis induced by TNF‐α blockade shows immunological features typical of the early phase of psoriasis development
por: Fania, Luca, et al.
Publicado: (2019)

The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis
por: Madonna, Stefania, et al.
Publicado: (2019)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes
por: Madonna, Stefania, et al.
Publicado: (2017)

Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment
por: Albanesi, Cristina, et al.
Publicado: (2009)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Inhibition of Inflammatory and Proliferative Responses of Human Keratinocytes Exposed to the Sesquiterpene Lactones Dehydrocostuslactone and Costunolide
por: Scarponi, Claudia, et al.
Publicado: (2014)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Extracellular Nucleophosmin Is Increased in Psoriasis and Correlates With the Determinants of Cardiovascular Diseases
por: D'Agostino, Marco, et al.
Publicado: (2022)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections
por: Pahar, Bapi, et al.
Publicado: (2020)

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2020)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice
por: Wang, Han, et al.
Publicado: (2019)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
por: Abdou, Asmaa Gaber, et al.
Publicado: (2018)

IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment
por: Mercurio, Laura, et al.
Publicado: (2018)

Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib
por: Yang, Qiao, et al.
Publicado: (2018)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021)

Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
por: Won, Jong Mun, et al.
Publicado: (2023)

Low-Frequency Low-Intensity Ultrasounds Do Not Influence the Survival and Immune Functions of Cultured Keratinocytes and Dendritic Cells
por: Scarponi, Claudia, et al.
Publicado: (2009)

Differential regulation of Janus kinase 3 (JAK3) in bovine preovulatory follicles and identification of JAK3 interacting proteins in granulosa cells
por: Ndiaye, Kalidou, et al.
Publicado: (2016)

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis
por: Bezzio, Cristina, et al.
Publicado: (2023)

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series
por: Xu, Qingqing, et al.
Publicado: (2023)

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
por: Kvist-Hansen, Amanda, et al.
Publicado: (2019)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of Keratinocytes
por: Arnold, Kimberly A., et al.
Publicado: (2023)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
por: Wen, Ji, et al.
Publicado: (2021)

Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders
por: Mercurio, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ra9numu1oba4mspdkgbariakvt